- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.
Indegene Limited officials are scheduled to hold 1x1 investor/analyst meetings on August 24-25, 2026. Participants include MFS International Singapore, ASK Investment Managers, Mirae Mutual Fund (online), Goldman Sachs Asset Management (in-person, Bengaluru), and Seven Canyon Advisors (online). No unpublished price sensitive information will be shared.
Indegene reported FY26 revenue of INR 3,510.5 Cr (up 23.6%) and PAT of INR 401.1 Cr. The company increased its dividend to INR 2.25/share. Strategic focus on AI-led operating models and integration of BioPharm (INR 882 Cr acquisition) is key for future growth and margin expansion.